These findings indicated that DOP treatment reduced CCl4-induced inflammation, suggesting that DOP might alleviate liver fibrosis by inhibiting inflammation through the TLR4/NF-κB pathway. The gene discussed is NFKB1; the disease is Hepatic fibrosis.